Dietary DHA supplementation causes selective changes in phospholipids from different brain regions in both wild type mice and the Tg2576 mouse model of Alzheimer's disease  by Bascoul-Colombo, Cécile et al.
Biochimica et Biophysica Acta 1861 (2016) 524–537
Contents lists available at ScienceDirect
Biochimica et Biophysica Acta
j ourna l homepage: www.e lsev ie r .com/ locate /bba l ipDietary DHA supplementation causes selective changes in phospholipids
from different brain regions in both wild type mice and the Tg2576
mouse model of Alzheimer's diseaseCécile Bascoul-Colombo a,b, Irina A. Guschina a, Benjamin H. Maskrey c, Mark Good b,
Valerie B. O'Donnell c, John L. Harwood a,⁎
a School of Biosciences, Cardiff University, Cardiff CF10 3AX, UK
b School of Psychology, Cardiff University, Cardiff CF10 3AT, UK
c School of Medicine, Cardiff University, Cardiff CF14 4XN, UK⁎ Corresponding author at: School of Biosciences, Card
Cardiff CF10 3AX, Wales, UK.
E-mail address: Harwood@cardiff.ac.uk (J.L. Harwood)
http://dx.doi.org/10.1016/j.bbalip.2016.03.005
1388-1981/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oArticle history:
Received 23 March 2015
Received in revised form 29 February 2016
Accepted 4 March 2016
Available online 9 March 2016Alzheimer's disease (AD) is of major concern in ageing populations and we have used the Tg2576 mouse model
to understand connections between brain lipids and amyloid pathology. Because dietary docosahexaenoic acid
(DHA) has been identiﬁed as beneﬁcial, we compared mice fed with a DHA-supplemented diet to those on a
nutritionally-sufﬁcient diet.
Major phospholipids from cortex, hippocampus and cerebellum were separated and analysed. Each
phosphoglyceride had a characteristic fatty acid composition which was similar in cortex and hippocampus
but different in the cerebellum. The biggest changes on DHA-supplementation were within ethanolamine
phospholipids which, together with phosphatidylserine, had the highest proportions of DHA. Reciprocal alter-
ations in DHA and arachidonate were found. The main diet-induced alterations were found in ethanolamine
phospholipids, (and included their ether derivatives), as were the changes observed due to genotype. Tg mice
appeared more sensitive to diet with generally lower DHA percentages when on the standard diet and higher
relative proportions of DHA when the diet was supplemented. All four major phosphoglycerides analysed
showed age-dependent decreases in polyunsaturated fatty acid contents.
These data provide, for the ﬁrst time, a detailed evaluation of phospholipids in different brain areas previously
shown to be relevant to behaviour in the Tg2576mousemodel for AD. The lipid changes observedwith genotype
are consistent with the subtle alterations found in ADpatients, especially for the ethanolamine phospholipidmo-
lecular species. They also emphasise the contrasting changes in fatty acid content induced by DHA supplementa-
tion within individual phospholipid classes.







Lipids are important constituents of brain, representing 50–60% dry
weight in adults [1]. Major components are cholesterol and
phospholipids (PL) such as phosphatidylcholine (PC), phosphatidyletha-
nolamine (PE), phosphatidylserine (PS), phosphatidylinositol (PI) and
sphingomyelin (Sph) [2,3]. With their high level of docosahexaenoic
acid (22:6n−3, DHA), the fatty acid composition of brain PL differs
signiﬁcantly fromother tissues. DHAand themajor n−6 polyunsaturated
fatty acid (PUFA), arachidonic acid (20:4n−6, AA) account for about 8%
and 6% of the dry weight of human brain, respectively [4], with DHA
representing up to 20% of the total fatty acids. In contrast, other PUFAiff University, Museum Avenue,
.
. This is an open access article undersuch as α-linolenic (18:3n−3, ALA) and eicosapentaenoic (20:5n−3,
EPA) acids comprise less than 1% of total brain fatty acids [5]. The DHA
content of different PL varies considerably and is especially high in PE
and PS [6].
A number of studies have investigated the association of n−3 PUFA
or DHA levels with Alzheimer's disease (AD) by examining post-mortem
autopsy brain samples. Reductions in DHA in different PL have been
reported by several labs. [7–11]. Recent studies have identiﬁed
plasmanyl and plasmenyl derivatives of PL, especially of PE, as being
notably reduced in AD brains [12–14].
In agreement with the above analyses, major epidemiological
surveys show that dietary n−3 PUFA and/or DHA signiﬁcantly reduce
the risk of developing AD [15–17]. Moreover, brain DHA levels are
positively associated with cognitive and behavioural performance [18].
Indeed, n−3 PUFA supplementation can improve brain function,
especially for complex tasks in normal individuals [19].the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Table 1
Fatty acid composition of the oil blend and the DHA diets.
Fatty acids Oil blend diet: standard rodent
feed + 5% oil blend
DHA diet: standard rodent feed
+ 5% DHA rich oil
12:0 0.05 ± 0.01 0.04 ± 0.01
14:0 0.08 ± tr. 0.38 ± tr.
16:0 1.65 ± 0.07 0.86 ± tr.
16:1 0.03 ± tr. 0.08 ± tr.
18:0 0.37 ± 0.01 0.07 ± tr.
18:1n−9 2.87 ± 0.13 1.66 ± 0.01
18:2n−6 2.06 ± 0.09 1.60 ± 0.02
18:3n−3 0.20 ± 0.01 0.17 ± 0.01
20:0 0.01 ± tr. 0.01 ± tr.
20:1 0.02 ± tr. 0.01 ± tr.




22:0 0.01 ± tr. 0.01 ± tr.
22:5n−3 N.D. 0.01 ± tr.
22:6n−3 N.D. 1.86 ± 0.04
24:0 N.D. N.D.
Total SAT 2.17 ± 0.08 1.37 ± 0.01
Total MUFA 2.93 ± 0.13 1.75 ± 0.01
Total PUFA 2.27 ± 0.10 3.64 ± 0.05
Total n−3 0.20 ± 0.01 2.04 ± 0.03
Total n−6 2.06 ± 0.09 1.60 ± 0.02
n−6/n−3 ratio 10.3 0.8
Results are represented asmeanpercentage of fresh diet (byweight)± SEM(n=3). N.D.,
not detected; tr., trace (less than 0.005); SAT, saturated fatty acids;MUFA,monounsaturat-
ed fatty acids; PUFA, polyunsaturated fatty acids. Analysis was carried out as detailed in
Section 2.6.
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been carried out, including studies on rodent models of AD. Dietary de-
ﬁciency of n−3 PUFA in rodents leads to a concomitant increase in brain
n−6 PUFA [20–22]. Moreover, n−3 PUFA supplementation not only in-
creased PL DHA levels [23–28] but was shown to improve learning and
memory [24,26–28]. In a rat AD model caused by amyloid-β (Aβ1–40)
injection, DHA and EPA were each shown to be of beneﬁt [29–31]. In
various transgenic mouse models feeding supplementary n−3 PUFA,
especially DHA, was associated with lower Aβ levels [10,11,32–37]
and such animals showed improved behaviour [35–37].
The above studies indicate that dietary DHA can be of beneﬁt for AD,
possibly by alleviating the amyloid pathology. Therefore, we decided to
examine the effects of dietary DHA on brain lipid composition in detail
by using the Tg2576mouse which expresses the Swedish double muta-
tion of the amyloid precursor protein (APP) gene. This was the ﬁrst
transgenic model for an AD mouse line to display cognitive defects
and, as such, has contributed greatly to the ﬁeld [38]. However, despite
its widespread usage, a comprehensive examination of the brain PL of
the Tg2576 mouse has not been undertaken previously. Moreover,
such data would permit comparisons with reported alterations in the
brain lipids of AD patients — a useful exercise for such a widely used
animal model for cognitive impairment.
Our data on the fatty acid composition of different PL revealed that
effects of diet were much greater than for genotype. Moreover, there
were notable differences between PL in the response of their composi-
tions to dietary DHA. The main increase in DHA was found in the etha-
nolamine phospholipids while the other main DHA-enriched PL, PS,
showed little change. All brain phosphoglycerides showed decreases
in PUFA contents between 12 and 16 months. It was noted that most
of the signiﬁcant genotypic changes in molecular species occurred for
ethanolamine lipids, just as reported for AD patients.
2. Material and methods
2.1. Chemicals
Standard chemicals and solvents of analytical or HPLC grade were
purchased from Fisher Scientiﬁc (Loughborough, UK) or Sigma (Poole,
UK). The dimyristoyl (di-14:0) phospholipid standards, (dimyristoyl-
phosphatidylethanolamine (DMPE), dimyristoyl-phosphatidylcholine
(DMPC) and dimyristoyl-phosphatidylserine (DMPS)) were obtained
from Avanti Polar Lipids Inc. (Alabaster, AL, USA). Other phospholipid
standards used for identiﬁcation were obtained from Sigma (Poole,
UK) and fatty acids were from Nu-Chek Prep Inc. (Elysian, MN, USA).
2.2. Diets and tissue samples
Mice were housed at 21 °C with a 12 h day/night cycle. Pups were
weaned at 5–6 weeks of age and allowed ad libitum access to rodent
chow and water up to 16 weeks. After this time, they were divided
randomly into groups fed either a DHA-enriched or an oil-blend control
diet. A standard maintenance rodent chow (Rodent Maintenance Diet
RM1; Special Diet Services, Essex, UK) was supplemented with 5%
DHA-rich oil (DHASCO, Martek Biosciences Corporation (now DSM)
Columbia, MD, USA) or 5% oil-blend (lard, palm oil, olive oil, coconut
oil, 3:3:3:1 by wt. to give a fatty acid mix similar to the average UK
diet). According to the manufacturer (Special Diet Services, Essex, UK),
the supplemented pellets (with the DHA-rich oil or the oil-blend)
contained approximately 12.8% protein, 7.2% oil, 3.9% ﬁbre and 5.6%
ash and had similar caloriﬁc values (3409 kcal/kg DHA diet, 3407 kcal/
kg oil-blend diet). The fatty acid content of the DHA-enriched diet and
the oil-blend control diet determined by GLC (Section 2.6) is presented
in Table 1. The diets were stored in sealed bags at−20 °C. Analysis of
the samples at 6-monthly intervals by GLC did not detect any changes
in fatty acid composition or the appearance of oxidative products.Food consumption was monitored in the period 9–12 months and was
not signiﬁcantly different for either diet or genotype.
12, 16 and 21 month-old mice were sacriﬁced and the brain
dissected into cortex, cerebellum and hippocampus. Samples were
weighed and snap-frozen in liquid nitrogen and stored at−80 °C.
2.3. Measurement of β-amyloid levels using an enzyme-linked immunosor-
bent assay
Cortex, hippocampus and cerebellum sampleswere homogenised in
2% (w/v) sodium dodecyl sulphate (SDS) solution. After centrifugation
(21,000 g for 1 h), soluble proteins including soluble β-amyloid proteins
were contained in the supernatant (SDS extract). Insoluble β-amyloid
proteins were extracted from the pellet using ice-cold 5 M guanidine
hydrochloride in PBS. The BCA™ Protein Assay kit (Pierce, Rockfore, IL,
USA) was used to measure the protein concentration of the samples.
β-Amyloid levels weremeasured by ELISA using commercial colorimet-
ric ELISA kits (BioSource International Inc., Camarillo, CA, USA) for
human Aβ1–40 (catalogue number KHB3482) and human Aβ1–42
(catalogue number KHB3442). Samples were analysed in duplicate. Aβ
levels were expressed as pg of Aβ per μg of protein, using the protein
concentration of the SDS extracts.
2.4. Lipid extraction
Lipidswere extracted frompreviously dissected andweighedmouse
brain tissue stored at−80 °C, using the method of Garbus et al. [39].
This is an adaption of the Bligh and Dyer procedure to give quantitative
extraction of polar lipids. PL internal standards for MS/MS analysis
(DMPE, DMPC and DMPS) were added at the one-phase initial stage.
The lipid-containing lower phase of the Garbus extract was washed
with fresh upper phase. The tissue residue was extracted a second
time by the Garbus et al. [39] method and, after washing (as above),
the lower phases were combined. They were taken to dryness under
nitrogen and resuspended in chloroform/methanol (2:1, v/v)
containing 0.1 mg/ml butylated hydroxytoluene and stored in glass
vials at−20 °C under nitrogen.
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Individual PLs were separated by two-dimensional TLC on silica gel
G 60 plates (Merck, Darmstadt, Germany). In order to separate PI from
PS, the TLC plates were pre-treated with a solution of 1.2% (w/v) boric
acid in ethanol:water (1:1, v/v) [40]. Chromatography used solvent
systems adapted from Katyal et al. [41]:
• Solvent system 1: chloroform:methanol:ammonium hydroxide
(65:35:10, by volume),
• Solvent system 2: n-butanol:acetic acid:water (90:20:20, by volume).
Plates were then sprayed with 0.2% (w/v) ANSA (8-anilino-1-naph-
thalene sulphonic acid) in dry methanol and lipids were visualised
under UV light (2UV Transilluminator UVP) [40]. The PLs were identi-
ﬁed routinely by comparison with phospholipid standards and con-
ﬁrmed using speciﬁc colour reagents [42].
2.6. Fatty acid analysis
Fatty acid methyl esters (FAMEs) were prepared from individual PL
classes separated by TLC, using acid-catalysed transmethylation. They
were stored in HPLC grade hexane and separated using a Clarus 500
gas chromatograph (Perkin-Elmer, Norwalk, Connecticut) ﬁtted with a
30 m × 0.25 mm (int. diam) Elite 225 polar capillary column (Perkin-
Elmer). The temperature programme used was: initial temperature of
170 °C for 3 min, followed by heating to 220 °C at 4 °C·min−1 and
held at 220 °C for 30 min. Samples were injected at a ﬂow rate of
20ml·min−1 with a split ratio of 20:1 and nitrogenwas used as the car-
rier gas. Pentadecanoic acid was used routinely as an internal standard.
Peaks corresponding to the different fatty acids were routinely identi-
ﬁed by comparison of their retention times to standards.
2.7. Phosphoglyceride analysis by electrospray ionisation tandem mass
spectrometry
Individual molecular species of the major phosphoglyceride classes,
PE, PC, PS and PI were analysed in mouse brain lipid extracts using
reverse-phase high performance liquid chromatography followed by tan-
dem mass spectrometry (RP-LC–MS/MS). Individual phosphoglyceride
molecular species were ﬁrst identiﬁed by direct infusion into the
electrospray source of a hybrid triple–quadrupole/linear ion trap mass
spectrometer (4000 Q-Trap, Applied Biosystems/MDS Sciex, Concord,
ON, Canada) at 10 μl/min. Phosphoglyceride molecular species were
identiﬁed by a mixture of Q1 scans and diagnostic headgroup scans
(PE = precursor 196− and neutral loss 141+; PC = precursor 184+;Table 2
Levels of amyloid-β in Tg2576 mice.




Cortex 4.5 ± 3.6 (44%) 48.0 ± 21.9
Hippocampus 18.9 ± 9.4 (46%) 16.0 ± 7.6 (
16 month-old
Cortex 31.2 ± 18.1 (96%) 223.6 ± 73.1
21 month-old
Cortex 31.8 ± 7.8 (107%) 284.3 ± 90.2
Hippocampus 128.8 ± 60.1 (84%) 227.9 ± 134.3
n.d., none detected. Figures in brackets show data for mice on the DHA-enriched diet as a perc
month-old, n= 3 for 16 and 21month-oldmice). Overall main effect of age p b 0.001 on amylo
of signiﬁcance.PS = neutral loss 87−; PI = precursor 241−). PL were identiﬁed by a
combination of MS/MS scans in negative mode to identify their sn−1
and−2 fatty acids and bond types, and by reference to published tables
of PL masses (www.lipidmaps.org) [43]. Diagnostic MRM transitions
were then calculated for each lipid based on their parent Nsn−2 fatty
acid in negative ionisationmode. Due to the poor ionisation of PC in neg-
ative ionmode, PCwasmonitored in both positive ionmode, monitoring
the [M+H]+ N 184 (protonated phosphocholine headgroup) transition,
and also in negative ionmode for the [M-CH3]− N sn−2 fatty acid transi-
tion to conﬁrm molecular identity. Internal MS/MS parameters for each
phospholipid class were optimised using the di14:0 internal standards.
To perform PL analysis, individual phosphoglyceride species from
murine brain lipid extracts were separated by RP-HPLC on the basis of
their acyl chain length on a Luna 3-μm C18 (2) 150 × 2 mm column
(Phenomenex Ltd., Macclesﬁeld, UK) with a gradient of 50–100%
solvent B over 10 min, followed by 30 min at 100% solvent B, where
A = methanol:acetonitrile:water, 60:20:20 (v/v) with 1 mM ammoni-
um acetate and B = 1 mM methanolic ammonium acetate at a ﬂow
rate of 200 μl/min and analysed in MRM scan mode as described
above, at a scan rate of 100 ms. Data was acquired and individual peak
areas integrated using Analyst 1.4.1 (Applied Biosystems). Each phos-
pholipid species was expressed as a ratio of the peak area relative to
the di-14:0 internal standard of the same lipid class. Di-14:0-PI was
not available commercially so di-14:0-PEwas used for the PI normalisa-
tion. For each phospholipid class, data are reported as percentages of the
total signal. The main species are presented in Figs. 6–9, but all species
analysed are presented in Supplementary Tables 31–45. We recognise
that mass spectrometry is not strictly quantitative with, for example,
varying ionisation values for individual lipid classes and for different
fatty acyl chain lengths. However, here we are comparing lipids from
two dietary regimes or two animal lines always under the same condi-
tions. The signals can be compared to the fresh weights by utilising the
results provided by the quantitative GLC data as stated in the legends to
Figs. 1–5.
In the results showing the molecular species, the letter “p” indicates
plasmalogen (plasmenyl).2.8. Statistical analyses
All statistical analyses using univariate ANOVA with genotype and
diet as factors were performed using SPSS 12.01 (SPSS Inc., USA).
p b 0.05 was considered statistically signiﬁcant.
Additional analyseswere carried out using the non-parametric Fried-
man test (SPSS Inc., USA). Signiﬁcant X2 values were evaluated using
post-hoc Wilcoxon signed-rank tests. The two analyses complimented
each other in terms of the main signiﬁcant differences.1–42
Soluble Insoluble
(84%) n.d. 6.6 ± 2.7 (86%)
37%) 1.0 ± 0.5 (48%) 1.1 ± 0.5 (47%)
(65%) 2.3 ± 1.7 (123%) 15.4 ± 4.1 (80%)
(88%) 3.5 ± 0.8 (92%) 25.2 ± 5.4 (83%)
(73%) 11.7 ± 3.6 (92%) 42.6 ± 17.8 (69%)
entage of the data for mice on the oil blend diet. Data show means ± SEM (n = 6 for 12
id levels. Despite numerical decreases, the impact of DHA did not reach conventional levels
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3.1. Accumulation of β-amyloid in cortex and hippocampus of transgenic
mice
As can be seen in Table 2, the Tg2576 mice accumulated both 1–40
and 1–42 β-amyloid with age. From 12 to 21 months of age, statistical
analysis conﬁrmed that there were increasing levels of amyloid detect-
ed with more of the 1–40 fragment and greater levels of insoluble
material, in general. Nevertheless, despite numerical decreases, the
impact of DHA diet on amyloid failed to reach statistical signiﬁcance.3.2. Fatty acid analysis of individual phospholipids
Following lipid class separations, we analysed the total fatty acid
composition of individual PLs from cortex, hippocampus and cerebel-
lum of 12 and 16 month-old WT and Tg mice. The data for 16 month-
old mice main fatty acids are given in Figs. 1–5. Full results for 12 and
16 month-old mice are in Supplementary Tables 1–30.Fig. 1.Main fatty acids in ethanolamine phospholipids from cortex (A), hippocampus (B) and c
diet (OB) or on the DHA diet. Results are represented asmean percentages of total fatty acids (T
Signiﬁcant effect of diet, *pb 0.05, **p b 0.01, ***pb 0.001; signiﬁcant effect of genotype,♦p b 0.0
(n= 12), 13.40 ± 0.48 (n= 11) μg fatty acids/mg fresh weight for the cortex, hippocampus an
diet or genotype.3.2.1. Fatty acid contents of ethanolamine phosphoglycerides
The main fatty acids identiﬁed in PE (and its ether derivatives) from
cortex, hippocampus and cerebellum of 16 month-old WT and Tg mice
on the oil-blend diet or on the DHA diet were 18:0, 18:1n−9, 20:4n−6
(AA) and DHA (Fig. 1). Signiﬁcant amounts of 16:0, 18:1n−7, 20:1n−9
and 22:4n−6 were also found. 18:1n−9 was more prevalent in cerebel-
lum. DHAwas amajor fatty acidwith 25% to 34% of total fatty acids in cor-
tex, 22% to 32% of total fatty acids in hippocampus and 19% to 27% of total
fatty acids in cerebellum. Percentages of DHA were signiﬁcantly higher
from DHA-fed mice and this increase was compensated by a decrease in
AA as well as its elongation product 22:4n−6. These simultaneous alter-
ations in DHA and n−6 fatty acids were observed in all three brain
areas (Fig. 1). Within the other fatty acids, diet only caused minor alter-
ations (if any) in proportions (Fig. 1, see also Supplementary Tables 1–6).
When comparing the three brain regions, the fatty acid composi-
tions (and their changes with diet) were similar for ethanolamine
phosphoglycerides in the cortex and hippocampus. The cerebellum
had lower percentages of 18:0, AA, 22:4n−6 and DHA than the two
other brain regions. These decreases weremainly compensated by larg-
er percentages of 18:1n−9 and 20:1n−9.erebellum (C) of 16 month-old wild-type (WT) and transgenic (Tg) mice on the oil blend
g OB (n= 3),WTOB (n= 3), Tg DHA (n= 3),WTDHA (n= 3))± SEM. Analysis by GLC.
5. The amount of ethanolamine lipidswas, on average, 12.09±0.77 (n=12), 11.48±0.35
d cerebellum, respectively. There were no signiﬁcant differences in the lipid amounts with
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from cortex, hippocampus and cerebellum between 12 months and
16months of age suggests an age-related decrease of the proportion
of very long chain PUFA such as AA, 22:4n−6 and DHA and con-
versely, an increased proportion of saturated fatty acids such as
16:0 and 18:0 (Supplementary Tables 1–6). This was especially
found in cortex and hippocampus. The main DHA decrease was ob-
served in cortex with a reduction of about 5% of total fatty acids
from 12 to 16 months. At 12 months, DHA diet increased the DHA
content by about 7% of total fatty acids regardless of the genotype.
Interestingly, although DHA feeding reduced the proportion of AA,
the latter's metabolic precursor 20:3n−6 was increased in PE and
other lipids (see Supplementary Tables). This may be due to re-
duced feedback from the lowered AA in the synthetic metabolic
pathway.
Although the effectwas not statistically signiﬁcant, it is interesting to
note that, at 16 months of age, the mean percentages of DHA in oil-
blend fed mice were constantly higher in WT mice than Tg mice and
this was reversed in the DHA-fed mice. At this age, the DHA diet in-
creased DHA levels by about 9% in Tg mice while it was only increased
by about 5% total fatty acids in WT mice. Thus, DHA supplementation
had a greater enhancing effect on brain DHA levels in Tg than WTFig. 2.Main fatty acids in choline phospholipids from cortex (A), hippocampus (B) and cerebellu
or on the DHAdiet. Results are represented asmean percentages of total fatty acids (Tg OB (n=
effect of diet, *p b 0.05, **p b 0.01, ***p b 0.001. The amounts of choline phosphoglycerideswere,
the cortex, hippocampus and cerebellum, respectively. There were no signiﬁcant differences inmice while WT mice on oil-blend diet maintained a higher percentage
of DHA than Tg mice on the same diet.3.2.2. Fatty acid contents of choline phosphoglycerides
Themain fatty acid in PC (and its ether derivatives)was 16:0 (Fig. 2).
18:0, 18:1n−9, 18:1n−7, AA and DHA were also present in signiﬁcant
amounts. Compared to ethanolamine phosphoglycerides, the percent-
age of palmitic acid (16:0), in particular, was elevated in all three
brain areas studied. AA was found at around a third of its percentage
in PE (Fig. 1) while DHA was much lower, especially in cortex and hip-
pocampuswith less than 5% and less than 3% of total fatty acids, respec-
tively. Diet changed DHA percentages by around a third and those of AA
by about half. As with PE, reciprocal changes in these PUFA were found
but 22:4n−6 was less than 1% in PC and, therefore, not shown in Fig. 2.
Where signiﬁcant changes in stearic and oleic acidswere caused by diet,
feeding the DHA-enriched diet lowered stearic acid and raised oleic
acid, as seen in PE.
Comparison of choline phosphoglycerides from the three brain areas
showed that the main fatty acid percentages were rather similar. How-
ever, the percentage of AA was lowest in cerebellum while DHA was
highest there.m(C) of 16month-oldwild-type (WT) and transgenic (Tg)mice on the oil blend diet (OB)
3),WTOB (n=3), TgDHA (n=3),WTDHA (n=3))± SEM. Analysis by GLC. Signiﬁcant
on average, 13.51±0.84, 13.51±0.33 and 12.54±0.31 μg fatty acids/mg freshweight for
the lipid amounts with diet or genotype.
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in the three brain areas (Supplementary Tables 7–12). As previously
noted for PE, this was greater in cortex and hippocampus.
As also observed with PE, Tg mice seemed more sensitive to diet,
with the maximum DHA percentages in all three regions obtained
with Tg mice on DHA diet.3.2.3. Fatty acid contents of phosphatidylserine
PSwasdominated by a high percentage of stearic acid (18:0) (Fig. 3).
In cortex and hippocampus, DHAwas the nextmost abundant fatty acid
while in cerebellum, oleic acid (18:1) (at about 30%) was double that of
DHA. AA and its elongation product, 22:4n−6 were relatively minor
components (2% or less) and were halved by feeding a DHA-diet. Inter-
estingly, in contrast to PE (Fig. 1), DHA feeding had little or no signiﬁ-
cant effect on the percentage of DHA in PS (Fig. 3).
Comparison of the composition of PS from cortex, hippocampus and
cerebellum between 12 months and 16 months of age suggests an age-
related decrease of the proportion of DHA and a conversely increased
proportion of saturated 18:0. From 12 to 16 months, DHA levelsFig. 3.Main fatty acids in phosphatidylserine (PS) from cortex (A), hippocampus (B) and cereb
(OB) or on the DHA diet. Results are represented as mean percentages of total fatty acids (Tg O
Signiﬁcant effect of diet, *p b 0.05, **p b 0.01, ***p b 0.001. The amounts of PS were, on averag
hippocampus and cerebellum, respectively. There were no signiﬁcant differences in the lipid adecreased by about 5% total fatty acids, on average (Supplementary
Tables 13–18).3.2.4. Fatty acid contents of phosphatidylinositol
PI contained the highest percentage of AA of all the phospholipids
examined (Fig. 4). Like PS (Fig. 3), it also contained up to about 50%
18:0. These two fatty acids accounted for 60–75% of the total. DHA
was relatively minor, especially in the hippocampus. It was highest in
the cerebellum and its percentage was approximately doubled with
DHA diet. Interestingly, eicosapentaenoic acid (20:5n−3, EPA) was de-
tected in the PI of all brain areas after DHA feeding (Fig. 4). This
contrasted with other phosphoglycerides where the proportion of EPA
was no higher than 0.5% (Figs. 1–3). Since EPA was not present in the
diet, this suggests a modiﬁcation of metabolism possibly including
retroconversion of DHA to EPA [44] which has been speciﬁcally demon-
strated in both humans and rats by the use of [13C]DHA [45]. The
appearance of EPA in PI only suggests that enzymes involved in its
formation may be selective for PUFA with a Δ5 cis double bond (like
EPA and AA).ellum (C) of 16 month-old wild-type (WT) and transgenic (Tg) mice on the oil blend diet
B (n = 3), WT OB (n = 3), Tg DHA (n = 3), WT DHA (n = 3)) ± SEM. Analysis by GLC.
e, 5.30 ± 0.20, 5.67 ± 0.49 and 4.99 ± 0.16 μg fatty acids/mg fresh weight for the cortex,
mounts with diet or genotype.
Fig. 4.Main fatty acids in phosphatidylinositol (PI) from cortex (A), hippocampus (B) and cerebellum (C) of 16month-old wild-type (WT) and transgenic (Tg) mice on the oil blend diet
(OB) or on the DHA diet. Results are represented as mean percentages of total fatty acids (Tg OB (n = 3), WT OB (n = 3), Tg DHA (n = 3), WT DHA (n = 3)) ± SEM. Analysis by GLC.
Signiﬁcant effect of diet, *p b 0.05, **p b 0.01, ***p b 0.001; signiﬁcant effect of genotype, ♦ p b 0.05. The amounts of PI were, on average, 1.80 ± 0.09, 1.66 ± 0.14 and 1.48 ± 0.04 μg
fatty acids/mg fresh weight for the cortex, hippocampus and cerebellum, respectively. There were no signiﬁcant differences in the lipid amounts with diet or genotype.
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cerebellum between 12months and 16months of age again suggests an
age-related decrease of the proportion of PUFA and conversely
increased proportions of 16:0 and 18:0. From 12 to 16 months, DHA
level decreased by about 1% total fatty acids, on average. Therewas little
effect of genotype (Fig. 4, Supplementary Tables 19–24).
3.2.5. Fatty acid contents of sphingomyelin
The other major phospholipid was sphingomyelin (Sph). Although
Sph contained a variety of fatty acids, including nervonic acid
(24:1n−9), its composition was heavily dominated by 18:0 (Fig. 5).
This represented up to about 85% of the total fatty acids in cortex and
was lowest in cerebellum (60–70%). There were no effects of diet on
the fatty acid composition in any of the three brain areas. As others
have noted [2,3,46–49], Sph contained virtually no AA or DHA.
Comparing the data from 12- and 16-month old mice (Supplemen-
tary Tables 25–30) suggested an age-relateddecrease in the proportions
of 22:0 and 24:1n−9 with reciprocal increases in 16:0 and 18:0.
The above analyses allowed some general conclusions. First, the ef-
fects of diet were greater than for genotype. Second, DHA supplementa-
tion caused different effects depending on the PL class. Quantitatively,
the largest effects of the DHA diet were on PE. Third, an age-dependent decrease in PUFA content of all phosphoglycerides was
found. Fourth, dietary supplementation with DHA generally reduced
the proportion of AA (and, where present, 22:4n−6) of PE, PC and PS
but had negligible effects on other fatty acids of PL. Fifth, Tg mice
seemed more sensitive to diet than WT and this was mostly observed
in PE and PC.
3.3. Analysis of brain phosphoglyceride molecular species composition
Following on from total fatty acid analysis, we undertook a lipidomic
approach to determine speciﬁc molecular species in brain
phosphoglycerides, in order to examine which species predominated
and whether changes on DHA supplementation were restricted to
particular lipids.
Negative-ion LC–MS/MS analysis of ethanolamine phosphoglycerides
demonstrated prominent peaks corresponding to the main molecular
species: 18:1p/18:1, 18:0/20:4, and 18:0/22:6 in cortex and hippocam-
pus and, in addition, 16:0p/18:1, 18:0p/18:1, 18:1/18:1 and 18:1p/20:1
in cerebellum (Fig. 6, Supplementary Tables 31–36). Feeding a DHA-
enriched diet increased all major DHA-containing species signiﬁcantly,
the effects being most notable in cortex and hippocampus, and particu-
larly in Tg mice (Fig. 6), as observed with GLC analysis (Fig. 1). In all
Fig. 5. Main fatty acids in sphingomyelin (Sph) from cortex (A), hippocampus (B) and
cerebellum (C) of 16 month-old wild-type (WT) and transgenic (Tg) mice on the oil
blend diet (OB) or on the DHA diet. Results are represented as mean percentages of
total fatty acids (Tg OB (n = 3), WT OB (n = 3), Tg DHA (n = 3), WT DHA (n = 3)) ±
SEM. Analysis by GLC. The amounts of Sph were, on average, 1.73 ± 0.14, 1.65 ± 0.11
and 1.14 ± 0.06 μg fatty acids/mg fresh weight for the cortex, hippocampus and
cerebellum, respectively. There were no signiﬁcant differences in the lipid amounts with
diet or genotype.
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or its plasmanyl-derivative (18:0p/22:6). As expected, the DHA diet re-
sulted in signiﬁcant decreases in all AA and 22:4-containing molecular
species.Withmice on oil-blend diet, themainmolecular species in cortex
and hippocampus was 18:0/20:4. For PE species which did not contain
PUFA, DHA feeding resulted in a signiﬁcant increase in the dioleoyl
(18:1) species (Fig. 6). The same overall patterns of change with diet
were seen for 12month-old and 16month-oldmice (Supplementary Ta-
bles 31–36). These included alterations in both PE and ethanolamine
plasmalogens (Supplementary Tables 31–36). Genotypic alterations
were found in both ethanolamine phosphoglyceride classes and in all
three brain areas (Supplementary Tables 31–36).
The main molecular species of PC, as revealed by LC–MS/MS, are
shown in Fig. 7. With the oil blend diet, the main species in the three
brain regions were 16:0/18:1, 18:0/18:1, 16:0/20:4, 18:0/20:4, 18:1/
20:4 and 16:0/22:6. The molecular species distribution of PC was very
similar for cortex and hippocampus while cerebellum showed some-
what greater amounts of 18:0/22:6 species while AA-containing species
were not as prevalent (Fig. 7), which was also seen with GLC analysis
(Fig. 2). Feeding DHA caused an increase in all DHA-containingmolecu-
lar species of PC while the AA-containing species were approximatelyhalved. This effect was particularly pronounced in Tg mice, as seen
with PE and with GLC analysis of PC (Fig. 2). There were few signiﬁcant
changes in other molecular species although one containing the Mead
acid (Δ5, 8, 11-eicosatrienoic acid, 16:0/20:3)was increased rather con-
sistently on DHA feeding (Fig. 7, Supplementary Tables 37–39). With
age, there seemed to be a number of changes to the molecular species
distribution in PC. For the cortex and hippocampus, 12 month-old
mice on the oil blend diet had increased 16:0/16:0 and 16:0/18:1 and
lower levels of 18:0/18:1, 18:0/20:4, 18:1/20:4 and all species contain-
ing DHA compared to 16 month-old mice. The same differences were
found for the cerebellum except that 18:1/20:4 was hardly altered
(Supplementary Tables 37–39).
Given the rather simple composition of PS major fatty acids (Fig. 3),
it was not surprising that themolecular species analysis was dominated
by 18:0-containing species (Fig. 8, Supplementary Tables 40–42). In
agreementwith the overall fatty acid composition (Fig. 3), themainmo-
lecular specieswere 18:0/18:1 and 18:0/22:6 (Fig. 8). Again, as reﬂected
in the total fatty acid changes with diet (Fig. 3), the DHA diet caused an
approximate halving of the 18:0/20:4 species but caused no signiﬁcant
increase in the 18:0/22:6 species (Fig. 8). In contrast to the other major
DHA-containing PL, PE, there were negligible changes caused to PS mo-
lecular species by genotype (Supplementary Tables 40–42).
The main molecular species of phosphatidylinositol (PI) for
16 month-old mice are shown in Fig. 9. As noted before (Fig. 4), the
DHA diet caused little change to AA in PI. Only in the cerebellum
were there signiﬁcant decreases in the AA-containingmolecular spe-
cies. This contrasted clearly from other phosphoglycerides (Figs. 1–3,
6–8). Other signiﬁcant alterations to the cerebellum PI, included in-
creases in 18:0/18:1, 16:0/22:6 and 18:0/22:6 (Fig. 9). Such changes
were also found in other brain fractions and at 12 months age (Sup-
plementary Tables 43–45). As with PS, genotype caused negligible
changes to the molecular species composition of PI (Supplementary
Tables 43–45).
4. Discussion
It is well known that β-amyloid accumulates in the brain of Tg2576
mice from about 8–9 months of age. For the ages used (12 and
16 months), as well as 21 months, we monitored the levels of
β-amyloid in the cerebellum, cortex and hippocampus of our Tg2576
mice and observed a signiﬁcant accumulation of the protein in the
cortex and hippocampus (Table 2) but not in the cerebellum (data not
shown). This agreed with previous data [50] as was the progressive in-
crease in β-amyloid levels with age [50,51]. The higher levels of insolu-
ble versus soluble fraction and the greater accumulation of the 1–40
fragmentwere also consistentwith published results [50,51]. In general,
the DHA-enriched diet gave lower levels of β-amyloid accumulation
(Table 2), as seen before [10,32,34,37].
Given the common usage of the Tg2576 amyloid mouse model [38,
52] and the widespread evidence for the connection between brain
lipids and AD, it is surprising that a detailed study of brain lipids in
this strain has not been undertaken before.
Our analyses of lipid classes and their molecular species give data
which is consistent with reported data for normal mice [11,53,54] and,
in particular, the results of Axelsen andMurphy [55]. The latter showed
that molecular species of phosphoglycerides had a fairly similar distri-
bution in hippocampus and cortex, as we have. However, here we
show that cerebellum lipids were somewhat different (Figs. 1–9) as
suggested in studies of other animals or humans (see [53,56]). This
may reﬂect the different functions of these brain regions where cortex
and hippocampus are involved in memory whereas the cerebellum is
associated with ﬁne grain motor control [57–59].
In animal brains, PE and PC are themain phospholipids [60,61] with
plasmalogen derivatives representing up to half of the PE class [2]. Our
data are in agreement, as is the observation that PI is enriched in AA
while PE and PS are the main DHA-containing phospholipids. However,
Fig. 6. Phosphatidylethanolamine (PE)mainmolecular species from the cortex (A), hippocampus (B) and cerebellum (C) of 16month-oldwild-type (WT) and transgenic (Tg)mice on the
oil blend diet (OB) or on the DHA diet. Results are expressed as percentages (%) of the total pool of lipids analysed for that class, using area for analyte (A) divided by the internal standard
(IS), for eachmolecular species (Tg OB (n=3),WTOB (n=3), TgDHA (n=3),WTDHA (n=3))± SEM. Analysis by LC–MS/MS. p, plasmenyl (or plasmalogen); signiﬁcant effect of diet,
*p b 0.05, **p b 0.01, ***p b 0.001; signiﬁcant effect of genotype, ♦ p b 0.05, ♦♦ p b 0.01.
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PL content of DHA is concentrated in ethanolamine phosphoglycerides
(Figs. 1 and 6, Supplementary Tables 1–6 and 31–36) whereas the
composition of PS is hardly changed (Figs. 3 and 8, Supplementary
Tables 13–18 and 40–42). Together with the preservation of selectiveacyl compositions within PL classes, this points to stringent metabolic
controls (see [62,63]) which merit further investigation.
DHA supplementation also caused a reciprocal signiﬁcant decrease
in the proportion of AA and, usually, 22:4n−6 in the different
phosphoglycerides even when the proportion of DHA did not show a
Fig. 7. Phosphatidylcholine (PC) main molecular species from the cortex (A), hippocampus (B) and cerebellum (C) of 16 month-old wild-type (WT) and transgenic (Tg) mice on the oil
blend diet (OB) or on theDHAdiet. Results are expressed as percentages (%) of the total pool of lipids analysed for that class, using area for analyte (A) divided by the internal standard (IS),
for each molecular species (Tg OB (n= 3), WT OB (n= 3), Tg DHA (n= 3),WT DHA (n= 3)) ± SEM. Analysis by LC–MS/MS. Signiﬁcant effect of diet, *p b 0.05, **p b 0.01, ***p b 0.001;
signiﬁcant effect of genotype, ♦ p b 0.05.
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on feeding a DHA-enriched diet are in agreement with results from pre-
vious studies described earlier where transgenic mice expressing AD
pathologies were fed DHA-enriched diets [10,33,34,36,64]. Not only dothese two fatty acids compete during phospholipid synthesis partly
due to the fact that the precursor fatty acids ALA and linoleic acid (LA)
are metabolised by the same sequence of desaturases and elongases
[65–67], but they are also precursors of bioactive mediators with
Fig. 8. Phosphatidylserine (PS) main molecular species from the cortex (A), hippocampus (B) and cerebellum (C) of 16 month-old wild-type (WT) and transgenic (Tg) mice on the oil
blend diet (OB) or on the DHA diet. Results are expressed as percentages (%) of the total pool of lipids analysed for that class, using area for analyte (A) divided by the internal
standard (IS), for eachmolecular species (Tg OB (n=3),WTOB (n=3), TgDHA (n=3),WTDHA (n=3))± SEM. Analysis by LC–MS/MS. Signiﬁcant effect of diet, **p b 0.01, ***p b 0.001.
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PGE2 and leukotriene B4 have pro-inﬂammatory properties, the n−3
derived molecules are non- or anti-inﬂammatory [67]. Furthermore, n
−3 derived resolvins, docosatrienes and neuroprotectins are all anti-
inﬂammatory and are suggested to have important functions in resolv-
ing inﬂammation and in protecting neurones [68,69]. This may reducelocal inﬂammation caused by the amyloid plaque formation in AD
brain and subsequently reduce the severity of the symptoms. This pro-
vides an important reason for the proposition that adequate dietary n
−3 PUFA are needed for good health, including reducing the
prevalence of AD. Several large-scale epidemiological studies have
shown beneﬁt of dietary ﬁsh oil or n−3 PUFA in reducing the risks of
Fig. 9. Phosphatidylinositol (PI) main molecular species from the cortex (A), hippocampus (B) and cerebellum (C) of 16 month-old wild-type (WT) and transgenic (Tg) mice on the oil
blend diet (OB) or on the DHA diet. Results are expressed as percentages (%) of the total pool of lipids analysed for that class, using area for analyte (A) divided by the internal
standard (IS), for each molecular species (Tg OB (n = 3), WT OB (n = 3), Tg DHA (n = 3), WT DHA (n = 3)) ± SEM. Analysis by LC–MS/MS. Signiﬁcant effect of diet, *p b 0.05,
**p b 0.01, ***p b 0.001; signiﬁcant effect of genotype, ♦ p b 0.05.
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ﬁsh oils or n−3 PUFA to alleviate AD symptoms. Not surprisingly such
trials (in patients with clear signs of neuronal damage, loss and demen-
tia) have not proven generally successful [70]. However, it is relevant to
note the possible positive effects of therapies with DHA-derivatives
[71]. Moreover, there have been beneﬁts of dietary DHA reported for
cases of early cognitive impairment [72–76]. This was also shown in an-
imal studies both with normal mice [28] or AD models [35–37,76].So far as age is concerned, we found a general decrease in the PUFA
contents of phosphoglycerides in 16 month-old mice compared to
12 month-old animals. This was found in all three parts of the
brain analysed and for all four phosphoglycerides. Our results are
consistent with cortex data for PE which was speciﬁcally analysed by
Han et al. [11].
We showed that the Tg2576mouse reacts to supplementary dietary
DHA in a broadly similar manner to wild-type animals. However, subtle
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classes of the Tg2576 mice compared to wild type. PE (and its
plasmalogens) appeared to show more changes than other PL classes.
For example, in 16 month-old mice, there were ten signiﬁcant
differences in ethanolamine phosphoglycerides but only three in all
the other phosphoglycerides combined (Supplementary Tables 32, 34,
36–42). Furthermore, signiﬁcantly changed ethanolamine lipids includ-
ed four plasmalogen species which contrasted to results reported for
rats [77]. However, our data bear comparison with analysis of brains
from Alzheimer's patients [7,8,11]. Thus, while total brain concentration
of different phosphoglycerides are little changed in AD by comparison
with control brains [13,14], there are reported changes for their fatty
acid compositions especially for PE [13]. Moreover, the plasmalogen spe-
cies of PE were notably decreased [11,12,14,78] and for the cortex this
was found to correlate with clinical dementia ratings [11]. In addition to
these changes, lower percentages of DHA were generally observed in Tg
mice on the standard diet, compared to WT mice on the same diet and,
in contrast, larger percentage increases in DHA were seen more in Tg
mice on DHA diet than WT mice on the same diet. This was mainly ob-
served in PE and PC and some of their speciﬁc DHA-containingmolecular
species. Although these observations might point to a deregulation of
lipidmetabolism affecting DHA accumulation in the brain of Tgmice, fur-
ther studies will be needed to clarify the question of a connection be-
tween AD and low brain DHA levels (particularly in PE).5. Conclusions
In conclusion, we demonstrate the selective incorporation of dietary
DHA into different PL with PE being favoured quantitatively. Further-
more, the signiﬁcant changes in both diacyl- and PE plasmalogens in
the amyloid (Tg2576) mouse model suggest a connection between PE
and behaviour, as proposed for AD patients. Further research should
extend these experiments as well as including certain sphingolipids
that are also altered in AD [14,45,79,80]. The latest advances in mass
spectrometry [81,82] and similar techniques [83,84] offer much prom-
ise in deﬁning detailed lipid distributions within different brain areas.
By suchmeans, we will gain more information that should help explain
the role of PE in relation to dementia (see [55]) and the potential protec-
tive effects of dietary DHA in preserving cognition. Our comprehensive
data with the amyloid Tg2576 model mouse add signiﬁcantly to the
body of evidence linking DHA-supplemented diets in mammals to
speciﬁc changes in brain lipid content and provide a basis for further
research as suggested above.Conﬂict of interest
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